[18F]fluorodeoxyglucose positron emission tomography for lung antiinflammatory response evaluation

Delphine L. Chen, Timothy J. Bedient, James Kozlowski, Daniel B. Rosenbluth, Warren Isakow, Thomas W. Ferkol, Betsy Thomas, Mark A. Mintun, Daniel P. Schuster, Michael J. Walter

Research output: Contribution to journalArticlepeer-review

43 Scopus citations

Abstract

Rationale: Few noninvasive biomarkers for pulmonary inflammation are currently available that can assess the lung-specific response to antiinflammatory treatments. Positron emission tomography with [ 18F]fluorodeoxyglucose (FDG-PET) is a promising new method that can be used to quantify pulmonary neutrophilic inflammation. Objectives: To evaluate the ability of FDG-PET to measure the pulmonary antiinflammatory effects of hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) and recombinant human activated protein C (rhAPC) in a human model of experimentally-induced lung inflammation. Methods: Eighteen healthy volunteers were randomized to receive placebo, lovastatin, or rhAPC before intrabronchial segmental endotoxin challenge. FDG-PET imaging was performed before and after endotoxin instillation. The rate of [18F]FDG uptake was calculated as the influx constant Ki by Patlak graphical analysis. Bronchoalveolar lavage (BAL) was performed to determine leukocyte concentrations for correlation with the PET imaging results. Measurements and Main Results: There was a statistically significant decrease in Ki in the lovastatin-treated group that was not seen in the placebo-treated group, suggesting attenuation of inflammation by lovastatin treatment despite a small decrease in BAL total leukocyte and neutrophil counts that was not statistically significant. No significant decrease in Ki was observed in the rhAPC-treated group, correlating with a lack of change in BAL parameters and indicating no significant antiinflammatory effect with rhAPC. Conclusions: FDG-PET imaging is a sensitivemethod for quantifying the lung-specific response to antiinflammatory therapies and may serve as an attractive platform for assessing the efficacy of novel antiinflammatory therapies at early phases in the drug development process. Clinical trial registered with www.clinicaltrials.gov (NCT00741013).

Original languageEnglish
Pages (from-to)533-539
Number of pages7
JournalAmerican journal of respiratory and critical care medicine
Volume180
Issue number6
DOIs
StatePublished - Sep 15 2009

Keywords

  • Biomarker
  • Drug development
  • Lovastatin
  • Neutrophils

Fingerprint Dive into the research topics of '[<sup>18</sup>F]fluorodeoxyglucose positron emission tomography for lung antiinflammatory response evaluation'. Together they form a unique fingerprint.

Cite this